1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc.

BSPM
Biostar Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
264.00Market Cap
Biostar Pharmaceuticals, Inc.
BSPM
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
TTM
FRC
16.5
31.83
48.15
63.91
69.24
36.07
32.07
29.65
12.27
1.04
0.12
Revenue per Share
4.12
4.91
7.07
13.85
9.16
-14.63
0.49
2.34
-11.36
-2.48
0.35
Basic EPS, GAAP
1.27
-1.04
3
7.04
4.17
-2.65
4.82
0.21
2.63
2.14
3.26
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.72
10.35
18.45
26.41
32.74
17
14.39
13.65
1.43
-1.1
-1.89
Book Value per Share
8.48
14.93
26.9
39.39
49.68
35.57
27.75
28.52
16.91
13.61
11.67
Tangible Book Value per Share
1
1
1
1
1
1
2
2
2
2
3
Basic Weighted Avg Shares
16
34
53
80
92
49
53
61
27
2
- -
Sales/Revenue/Turnover
30.5
22.89
28.32
29.43
19.75
-24.62
2.05
2.12
-40.07
-149.48
893.3
Operating Margin (%)
1
1
1
1
1
2
3
3
2
1
1
Depreciation Expense
4
7
10
17
12
-20
1
5
-25
-6
1
Net Income, GAAP
17.17
13.38
28.82
25.89
32.62
- -
69.54
- -
- -
- -
73.95
Effective Tax Rate (%)
24.95
19.73
19.69
21.67
13.24
-40.55
1.53
7.89
-92.57
-238.98
294.01
Profit Margin (%)
3
7
24
36
54
29
31
35
9
2
-4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
16
23
41
60
76
58
63
72
44
37
36
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
71.79
66.75
64.87
31.52
- -
3.46
- -
- -
- -
-32.52
Return on Capital (%)
- -
59.77
49.77
64.88
31.77
-59.94
3.45
18.67
-159.79
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
5
4
3

Working Capital

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
Total Current Assets
6
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
6
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
5
Payables & Accruals
3
3
3
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-11.2%
-16.69%
Free Cash Flow
- -
124.71%
-15.56%
Net Income, GAAP
- -
-112.87%
-77.31%
Sales/Revenue/Turnover
- -
-34%
-91.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
7
14
4
2
27
2016
1
1
1
- -
2
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.07
-0.22
-0.57
- -
-11.36
2016
-0.28
-3.12
-0.71
- -
-2.48
2017
-0.38
-0.5
-0.05
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
Similar Companies
Dermapharm Holding SE (DMPHF)
Sunset Island Group, Inc. (SIGO)
CBD Global Sciences Inc. (CBDNF)
JW Pharmaceutical Corporation (001067.KS)
Molecule Holdings Inc. (MLCL.CN)
Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)
Business
Biostar Pharmaceuticals, Inc. (BSPM) develops, manufactures, and commercializes biopharmaceutical products focused on traditional Chinese medicine and botanical drugs for the treatment of chronic diseases. The company offers a portfolio of proprietary products including its flagship Fuzheng Kangai Granules for cancer support; Kangnaoshuai Oral Liquid and related formulations for viral infections and immune modulation; and Tianqi Capsule and other botanical extracts targeting diabetes and cardiovascular conditions; alongside services in research, clinical trials, and regulatory compliance for herbal-based therapeutics. Headquartered in Xianyang, Shaanxi Province, China, and founded in 2003, Biostar operates primarily in the Asia-Pacific region, serving pharmaceutical distributors, hospitals, and clinics in China with expansion into select international markets. In recent developments, the company announced a strategic partnership with a leading Chinese biotech firm in late 2024 to co-develop next-generation immune-oncology therapies based on its proprietary botanical compounds; completed a $15 million Series B funding round in early 2025 led by domestic venture capital to fund Phase III clinical trials for its diabetes pipeline; and launched a new manufacturing facility in 2025 compliant with international GMP standards to support export growth into Southeast Asia.